Vascular Endothelial Growth Factor Inhibitor

Name

Vascular Endothelial Growth Factor Inhibitor

Accession Number

DBCAT003817

Description

Not Available

Drugs

Drug	Drug Description
Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Ranibizumab	A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
Aflibercept	A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer
Brolucizumab	An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.

Drugs & Drug Targets

Drug	Target	Type
Bevacizumab	Vascular endothelial growth factor A	target
Bevacizumab	Complement C1q subcomponent subunit A	target
Bevacizumab	Complement C1q subcomponent subunit B	target
Bevacizumab	Complement C1q subcomponent subunit C	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Bevacizumab	High affinity immunoglobulin gamma Fc receptor I	target
Ranibizumab	Vascular endothelial growth factor A	target
Aflibercept	Vascular endothelial growth factor A	target
Aflibercept	Placenta growth factor	target
Aflibercept	Vascular endothelial growth factor B	target
Brolucizumab	Vascular endothelial growth factor A	target